Articles tagged with Leukemia
Researchers at Nova Southeastern University have identified a genetic marker, NER gene expression levels, to predict early relapse in pediatric acute lymphoblastic leukemia (ALL) patients. This finding has the potential to guide targeted treatment and improve patient outcomes.
A Syracuse University physicist has developed tiny sensors that can detect and analyze protein-protein interactions in blood serum, which could lead to improved cancer detection. The technology, known as nanobiosensors, uses a nanopore to measure changes in electric current when proteins are present.
Scientists at Cold Spring Harbor Laboratory have identified ZFP64 as the single key to the cascade of events leading to mixed lineage leukemia (MLL), an aggressive blood cancer. Shutting down this protein may be a cure for MLL, which predominantly occurs in infants and is difficult to treat.
A study published in Cell Stem Cell found that the PPM1D gene confers a survival advantage to blood cells exposed to chemotherapy, potentially favoring the development of secondary leukemia. The research suggests that the presence of this gene and other mutations should be considered when choosing chemotherapies.
A low-fat diet has been shown to increase the survival rate of obese children with acute lymphoblastic leukemia by five times compared to a high-fat diet. This dietary intervention could potentially help kill cancer cells and improve treatment outcomes.
Researchers in Barcelona have received an ERC Synergy grant to study chronic lymphocytic leukemia at unprecedented resolution using single-cell analysis. The BCLL@las project aims to generate comprehensive information from thousands of individual cells, leading to novel insights into the origin and evolution of cancer.
Leukemia undercuts normal cells' ability to consume glucose, leading to a diabetic-like condition that favors cancer growth. Researchers have identified key strategies, including manipulating insulin production and gut bacteria, which can be targeted with low-tech therapies like serotonin supplementation.
Loyola will produce a more purified CAR-T cell product potentially reducing toxicities and costs. The Leukemia Research Foundation is supporting the research with a $250,000 grant.
A new study of 96 patients with chronic lymphocytic leukemia (CLL) found that those experiencing stress have higher levels of cancerous cells and cytokines in their blood. The researchers also discovered a link between stress and disease severity, even after controlling for other factors.
Scientists have introduced a microfluidic chip for manipulation and nucleic-acid analysis of individual cells. The technique uses dielectrophoresis to trap and analyze cells efficiently, overcoming conventional methods' limitations. This innovation paves the way for personalized medicine and improved diagnostics.
A team of researchers has discovered a protein called LEDGF/p75 that contributes to the regulation of gene expression in mixed lineage leukemia. The study found that this interaction is strongly modulated by phosphorylation from an enzyme called casein kinase 2, providing a new therapeutic route against the cancer.
A large cohort study found CLL patients have a 600% higher risk of melanoma compared to the general population. Close monitoring for early detection is crucial in managing this skin cancer with targeted therapies.
A study reveals that blocking heat shock transcription factor 1 (HSF1) signaling in T cell acute lymphoblastic leukemia (T-ALL) could represent a new approach in treating the aggressive disease. The discovery identifies a subset of T-ALL patients most likely to benefit from a new therapy.
Children with leukemia experience frequent vertebral fractures during chemotherapy, often persisting into adulthood. Vertebral deformities are more common in older children and those with severe collapse.
Researchers found that bacterial signals play a crucial role in developing pre-leukemic myeloproliferation, a precursor condition to leukemia, in mice with TET2 mutations. The study suggests that targeted treatments could reverse the disease by blocking aberrant IL-6 signals.
Researchers at Boston University School of Medicine identified ubiquitin-fusion degradation 1 (UFD1) as a key protein in aggressive T-cell leukemia. Reducing UFD1 levels by 50% inhibited leukemia development without impacting healthy tissues.
Researchers discovered genetic defects typical in ANKL, a shared genetic background with NK- and T-cell malignancies, and novel gene amplifications in the JAK-STAT signaling pathway. Potential drug candidates were found, including JAK inhibitors that could improve treatment for various NK-cell malignancies
Researchers identified a fourth gene, IKZF1, associated with childhood leukemia predisposition, expanding cancer screening options. Germline variants in IKZF1 increase the risk of developing B-cell acute lymphoblastic leukemia (ALL), a common pediatric cancer.
Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a new molecular cause of aggressive infant leukemia in children. The study found that changes in genes in white blood cells disrupt cell growth control, leading to the production of abnormal proteins that facilitate leukaemia.
Research from St. Jude Children's Research Hospital found that leukemia itself may increase the risk of long-term neurocognitive problems, even before treatment starts. Elevated biomarkers in cerebrospinal fluid indicate injury to brain cells, suggesting a complex interaction among genetics, treatment intensity, and other factors.
Two genes, JAK3/STAT5 and HOXA9, have been found to cooperate in triggering leukemia development. This cooperation leads to more rapid and aggressive disease progression. The discovery provides a basis for targeted therapies, not only for acute lymphoblastic leukemia but also for other leukemias.
A new technique using mass cytometry predicts relapse in acute lymphoblastic leukemia patients with 85% accuracy, identifying a subset of malignant cells that predispose to relapse. The method could lead to more precise treatment and targeted therapies for high-risk patients.
A global clinical trial of CAR T-cell therapy tisagenlecleucel found that 61% of children and young adults achieved complete remission after treatment, with durable responses lasting months or years. Most side effects were short-lived and reversible, with overall survival rates exceeding 90% at six months.
Researchers found that germline variations in the tumor suppressor gene TP53 predispose children to develop leukemia and increase their chances of developing a second cancer. The variants are associated with reduced gene activity and were five times more frequent in pediatric ALL patients than those without the disease.
Patients with advanced leukemia who rely on blood transfusions face barriers to quality end-of-life care, including limited hospice services and higher hospital deaths. Research suggests that improving access to blood transfusions could increase hospice care use among these patients.
Research found that leukemia patients who rely on blood transfusions face difficulties enrolling in hospice care, leading to shorter hospice stays and delayed access to palliative care. The study suggests that adding support for transfusions to the Medicare hospice benefit could maximize its benefits.
Research at Lund University found that HLF gene's failure to shut down leads to inadequate lymphocyte development, resulting in a single type of immune defense. The study aimed to identify mechanisms for breaking down leukemia, an aggressive blood cancer with poor prognosis.
Barbara Savoldo, MD, PhD, received a three-year grant to support research into an investigational CAR T-cell treatment for acute lymphoblastic leukemia with a built-in safety switch. The goal is to adapt an 'off switch' to reduce potentially lethal side effects of immunotherapy treatments.
A study by St. Jude Children's Research Hospital found that young leukemia patients who received the flu vaccine were still susceptible to flu infections, highlighting the need for additional measures to protect vulnerable individuals. Researchers emphasize the importance of hand washing and other precautions.
Hui Feng's research aims to understand why T-ALL is so aggressive and resistant to treatment. The grant will support further studies on the role of a novel protein contributor to leukemia's aggressiveness and its potential targeting through available drugs.
A team of scientists has identified a protein called TOX that drives the initiation and growth of an aggressive form of leukemia. TOX is expressed in 95 percent of human T-ALL cases and required for cancer's growth and persistence, offering new targeted treatment approaches.
Scientists at UC San Diego uncover a previously unknown link between non-coding DNA regions and the formation of immune cells. The discovery reveals a precise mechanism for the pairing of promoter and enhancer elements, which brings them into close proximity to initiate immune cell development.
Researchers at UT Southwestern Medical Center found that vitamin C regulates stem cell function and suppresses leukemia development. The study used mice with limited ascorbate production to mimic human levels and discovered a link between ascorbate, DNA modifications, and Tet2 enzyme activity.
Researchers have identified the KMT2A gene translocations as a common underlying cause of infant and treatment-related leukemias. The Penn/CHOP team has also found that topoisomerase II cleavage clusters in specific regions of the genome, which may play a role in DNA damage repair and cancer development.
A team of researchers has discovered that a DNA-cutting enzyme plays a broad role in driving abnormal genetic rearrangements, including translocations that cause cancer. The study identified specific sites of DNA damage along the entire genome of human leukemia cells.
Researchers developed an anti-PD-1 antibody that blocks PD-1/PD-L1 interaction, reinvigorating antivirus immune response and decreasing BLV counts. The new treatment could be effective against various intractable infectious diseases in cows.
Researchers discovered a protein signature that predicts leukemia, which could lead to novel treatments. The activation of STAT5 causes competition among proteins, leading to acute lymphoblastic leukemia.
A study published in Leukemia reveals an epigenetic lesion that correlates with the activation of a powerful oncogene capable of malignizing lymphocytes, leading to acute T-cell leukemia. The research suggests that targeting this gene may offer new treatment options for patients with this aggressive type of cancer.
A study using human stem cells found that deep space radiation may increase the risk of leukemia in humans. The research team identified a dietary supplement as a potential protector against these effects.
The OHSU Knight Cancer Institute research team discovered a previously unreported flaw in the standard leukemia assay, which can lead to non-functional mutations appearing functional. They recommend an additional sequencing step to improve the assay's accuracy and reproducibility.
Researchers identified L-asparaginase in yeast that efficiently kills leukemia cells with low toxicity to healthy cells. The enzyme depletes asparagine, a crucial amino acid for cancer cell survival, leading to apoptosis and inducing programmed cell death.
Researchers at Northwestern University have discovered a genetic driver of mixed lineage leukemia, a rare and deadly form of childhood leukemia. They identified a targeted molecular therapy that halts the proliferation of leukemic cells by stabilizing the wild-type MLL protein, which drives cancer.
Researchers identified gene mutations associated with steroid resistance in pediatric T-cell acute lymphoblastic leukemia, leading to poor clinical outcomes. A new therapeutic approach targeting individual signaling proteins restored steroid sensitivity in leukemic cells from patients.
The technology platform, Phenotypic Personalized Medicine, uses visual representations to identify optimal drug and dose combinations for patients with acute lymphoblastic leukemia. This approach reduces side effects while maintaining or enhancing efficacy, offering a game-changer for cancer treatment.
A University of Liverpool study found that reducing the dose of leukemia drug tyrosine kinase inhibitors (TKI) can safely reduce side effects in patients with chronic myeloid leukemia. Patients who achieved stable molecular remission levels showed no evidence of leukaemia rebound after cutting their TKI dose, with some reporting signif...
A recent study identifies inherited genetic mutations in the IKZF1 gene as a major risk factor for pediatric ALL. The variants affect protein Ikaros, crucial for white blood cell development, and reduce cancer cells' sensitivity to chemotherapy drug dasatinib.
A study by The University of Texas MD Anderson Cancer Center found pre-leukemic mutations can predict the development of therapy-related myeloid neoplasms (t-MNs), a leukemia with poor prognosis. Patients with these mutations are at higher risk, and detecting them earlier could help prevent or treat t-MNs.
Researchers from Penn Medicine present early results from studies of CAR T cell therapy for multiple myeloma and relapsed/refractory acute lymphoblastic leukemia, showing high efficacy and safety profiles. The findings build on the team's work in CAR T cell therapies dating back to 2010.
Researchers have created a mouse model that replicates the human genetic flaw causing infant leukemia, making it easier to study. The model mimics the disease found in humans both phenotypically and molecularly, with all mice developing Pro-B ALL identical to patient cases within 22 weeks.
Researchers at CHLA are developing a new treatment approach for patients with relapsed acute lymphoblastic leukemia (ALL) by targeting the molecule integrin alpha4, which shelters leukemia cells from chemotherapy. The goal is to develop a novel inhibitor of this molecule for clinical use.
Researchers have discovered a new high-risk subtype of acute lymphoblastic leukemia (ALL) characterized by chromosomal rearrangements involving the MEF2D gene. A possible targeted therapy, panobinostat, has been shown to stop proliferation of human leukemic cells with this rearrangement.
Researchers find that specific DNA mutations in bone cells can cause nearby blood stem cells to develop leukemia. A new class of drugs has been identified to dampen this 'neighbor cell effect', offering hope for improved treatment options for Noonan syndrome patients.
Researchers have determined that combining CX-4945 and JQ1 can efficiently kill T-cell acute lymphoblastic leukemia cells while sparing normal blood cells. The findings provide new hope for the treatment of refractory/relapsed T-cell leukemia, a form of cancer with a high mortality rate.
Researchers at Dana-Farber Cancer Institute have found that CML stem cells die in response to inhibition of the protein Ezh2, suggesting a potential cure for some patients. Adding Ezh2-targeting agents to standard treatment could dramatically shorten the treatment period and achieve a cure.
A recent study has shed light on the pathogenesis of DNA breakpoints associated with leukemia, revealing a mechanism that explains up to 90% of DNA damages in the most common type of childhood leukemia. The study identified a new high-risk subtype of leukemia characterized by abnormal expression of enzymes causing DNA damage.
Researchers discovered leukemia stem cells in fatty tissue of obese patients were more resistant to chemotherapy, using fatty acids as their energy source and actively signaling fat for lipolysis. This adaptation could help explain poorer outcomes in obese patients, potentially shedding light on new strategies to target cancer stem cells.
A randomized Phase III study found nearly 81% of patients in the inotuzumab ozogamicin group achieved complete remission, compared to 31-41% with standard therapies. The drug enabled 41% of patients to proceed with stem cell transplants, increasing their chances of a curative treatment.
HTLV-1, a retrovirus that co-exists with humans, infects 30 million people worldwide. Persistent infection is attributed to CTCF, which controls viral DNA integration into human DNA. This discovery may lead to new prevention and treatment strategies for refractory leukemia.
Leukemia cells exhibit stiffer mechanical signatures compared to healthy cells. The study suggests that these mechanical data can be used to grade the loss of cell mechanical functions depending on leukemia progression. This approach may aid in cancer diagnosis and provide insights into disease evolution
Researchers at the University of Zurich have discovered a new way to kill off resistant leukemia cells via necroptosis, a cell death program that can bypass traditional apoptosis. SMAC mimetics, which activate necroptosis, showed promise in killing leukemia cells in 33% of patient samples tested.